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Chronic obstructive pulmonary disease (copd) is a major cause of illness and death throughout the world. It affects about 10% of the general population,1 but its prevalence among heavy smokers can reach 50%.2 COPD 
is the fourth leading cause of death in most industrialized countries, and it is pro-
jected to be the third leading cause of death worldwide by 2020.1 Tobacco smoking 
is the primary risk factor for the development of COPD, but other factors, such as 
burning biomass fuels for cooking and heating, are important causes of COPD in 
many developing countries.3,4
A principal feature of COPD is a limitation of airflow that is not fully reversible 
and is associated with an abnormal inflammatory response in the small airways 
and alveoli. The principal abnormalities in small airways are the presence of an 
inflammatory cellular infiltrate and a remodeling that thickens the airway wall, 
thereby reducing the airway diameter and increasing resistance to flow5 (Fig. 1). 
Additional features are prominent inflammatory infiltrates in the alveolar walls, 
destruction of alveoli, and enlargement of air spaces. These anatomical hallmarks 
of emphysema reduce the elastic pressure that generates expiratory flow6 (Fig. 2). 
Chronic bronchitis, a condition that according to some authors has little to do 
with the development of airf low obstruction,7 develops in approximately 50% of 
smokers.
Several mechanisms may contribute to these abnormalities. In 1964, researchers 
reported that a deficiency of alpha1-antitrypsin was associated with emphysema.
8 
A few years later, neutrophil elastase was reported to be the target of alpha1-anti-
trypsin.9 These findings, together with the observation of increased numbers of 
neutrophils and macrophages in the lungs of smokers, pointed to a connection be-
tween neutrophil elastase and macrophage proteinases as the primary effectors of 
lung destruction in COPD, a premise that still prevails.10,11 Other, complementary 
mechanisms have been proposed more recently, including oxidative stress due to 
cigarette smoking or to the increase in activated neutrophils and macrophages,12 as 
well as apoptosis of endothelial and epithelial cells. The apoptosis results in part 
from the down-regulation of vascular endothelial growth factor (VEGF), which is 
required for the growth and survival of endothelial and alveolar cells. These events 
interfere with lung maintenance and repair, which are necessary to overcome the 
sustained injury imposed by cigarette smoke.13 In addition, residual apoptotic debris 
can promote further inflammation and an immune reaction.14 Another possible 
mechanism involves viral infections, which are common in smokers. Viruses can 
add to the inflammatory milieu promoted by smoking.7,15 Age-related alterations, 
such as epigenetic changes, low-grade chronic inflammation, and cell senescence, can 
also contribute to the development of emphysema by enhancing inflammation and 
impairing tissue repair.16 All these mechanisms point to a central role of the inflam-
matory response to inhaled particles and pollutants in the pathogenesis of COPD.1
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Inflammation mediated by T cells in the 
lung, which persists for years after cessation of 
smoking, has been identified as a key compo-
nent of COPD.17,18 These findings suggest that 
the immune response is involved in the patho-
genesis of COPD and that COPD could be an 
autoimmune disease triggered by cigarette smok-
ing.19-21 In the 5% of patients with COPD who 
are nonsmokers, the disease seems to be associ-
ated with organ-specific autoimmunity.22
In this article, we review the proposed mech-
anisms leading to COPD and the emerging evi-
dence that progression of the disease is the result 
of T-cell–mediated inflammation. T cells could be 
activated by antigens released during smoking-
induced lung injury. We have divided these mech-
anisms into three steps that may be involved in 
the development of COPD.
Mech a nisms Le a ding t o COPD
Step 1 — Initial Response to Cigarette Smoke
Innate and adaptive immunity are components of 
an integrated system in which cells and mole-
cules function cooperatively. The innate immune 
response relies not on antigen-binding receptors 
but on pattern-recognition molecules, and unlike 
the adaptive immune response, it is not associated 
with long-lasting protective immunity. Innate im-
munity is a rapid, nonspecific response to mi-
crobes and tissue injury that stimulates and influ-
ences the relatively slow development of specific 
adaptive immune responses.23
How irritants such as cigarette smoke trigger 
an innate immune response is unknown, but the 
“danger hypothesis” of Matzinger24 is a plausible 
explanation. Matzinger has proposed that it is not 
the presence of a microbe itself that alerts the 
immune system to respond but rather the cellu-
lar stress or tissue damage (danger signals) result-
ing from infection. Toll-like receptors (TLRs), of 
which there are about 15 different types, are 
sensors on cells of the innate immune system 
that recognize molecular patterns displayed by 
pathogens. Some TLRs can also initiate immune 
responses against injured tissue.25 Each puff of 
a cigarette contains more than 2000 xenobiotic 
compounds and 1014 free radicals that injure lung 
epithelial cells to a degree that is directly pro-
portionate to their concentration.26,27 Breakdown 
of connective tissue also occurs in humans who 
smoke,28,29 as it does in mice exposed to ciga-
rette smoke.30 Products derived from epithelial-
cell injury can act as ligands for TLR4 and TLR2; 
when either is cross-linked by its corresponding 
ligand it will activate nuclear factor κB (NF-κB),31,32 
inducing epithelial cells to produce mediators of 
inflammation. These mediators activate alveolar 
macrophages and neutrophils,33,34 which in turn 
secrete proteolytic enzymes and, together with 
reactive oxygen species, damage lung tissue fur-
ther.35,36
Exposure to infectious or environmental in-
sults, tissue trauma, oxidative stress, or cell 
death37 could release sequestered autoantigens,38 
modify proteins, damage mitochondria, and re-
lease DNA from apoptotic cells.39 The adaptive 
immune system can recognize these products as 
foreign antigens and trigger an immune reac-
tion.37,40-43 These and other similar mechanisms 
have been implicated in rheumatoid arthritis, 
atherogenesis, multiple sclerosis, and systemic 
lupus erythematosus.37,38,40 In smokers, such anti-
gens could be released as a result of necrosis and 
apoptosis of epithelial and endothelial cells and 
extracellular-matrix injury.41-43 Self-antigens are 
not by themselves sufficient for the development 
of an immune response or an autoimmune dis-
ease; however, TLRs will link innate and adap-
tive immunity, enhancing the pathogenic poten-
tial of those antigens.44 Inflammatory lung injury 
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Figure 1. Specimens from the Small Airways in the Healthy Lung of a Nonsmoker 
and the Lung of a Smoker with COPD.
In the specimen of the small airways (membranous bronchioles) from the 
healthy lung of a nonsmoker (Panel A), the airway walls are thin, and intact 
alveoli are attached along its circumference. In a comparable specimen from 
the lung of a smoker with COPD (Panel B), the diameter of the airway is nar-
rowed, the airway wall is thickened, and many of the alveolar attachments 
are broken. CD8+ T lymphocytes (in red) infiltrate the airway wall in the spec-
imen from the smoker with COPD (Panel B) but not in the specimen from 
the nonsmoker (Panel A) (immunostaining with antihuman CD8; counter-
stained with hematoxylin). Images courtesy of Dr. Fiorella Calabrese.
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can disrupt the extracellular matrix, and break-
down products such as hyaluronate45 and bigly-
can46 can ligate TLR2 and TLR4.47 The end re-
sult is that macrophages and dendritic cells 
produce cytokines and chemokines that orches-
trate the inflammatory conditions required to ac-
tivate the adaptive immune system.44,47 In mice, 
lung inflammation induced by cigarette smoke 
depends on the presence of TLR4 and myeloid 
differentiation factor 88, an adapter protein that 
stimulates NF-κB.48
We refer to this chain of events as step 1 in the 
progression of COPD and propose that in most 
smokers the disease process will not advance if 
innate inflammation is minimized and the events 
described in step 2 and step 3 do not take place 
(Fig. 3). Patients at step 1 are most likely smok-
ers with normal lung function or stage 1 COPD 
as defined by the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD).
Step 2 — T-Cell activation and Proliferation
Immature dendritic cells alert the adaptive im-
mune system to the presence of incoming patho-
gens or to tissue injury.25,44,49,50 These cells ma-
ture when the TLRs they display bind to a ligand. 
Mature dendritic cells express high levels of class 
II major-histocompatibility-complex (MHC) pro-
teins and the costimulatory molecules CD80 and 
CD86, which direct them to local lymph nodes, 
where they present antigens to T cells.51 Expres-
sion of interleukin-12 by dendritic cells activates 
the signal transducer and activator of transcrip-
tion 4 (STAT4), which induces T cells to differ-
entiate into type 1 helper (Th1) T cells, which 
in turn produce interferon-γ. In smokers with 
COPD, there is a marked increase of mature den-
dritic cells in the peripheral airways52,53 that is 
most likely related to the high expression in the 
lungs of the dendritic-cell chemoattractant 
CCL20.52 There is also an increase in CD4+ T cells 
expressing STAT4 in the lungs. Consistent with 
these events in the chain of causation is the ob-
servation that the expression of STAT4 and 
interferon-γ correlates with the degree of airflow 
limitation in COPD.54
It is likely that material in the lungs of smok-
ers from stressed, injured, and necrotic cells55,56 
and from apoptotic cells57 is taken up by den-
dritic cells and presented by dendritic cell–MHC 
class I molecules to CD8+ T lymphocytes. Such 
T cells are abundant in the lungs in COPD.58
Naive, quiescent T cells cannot enter the lung 
parenchyma outside blood vessels,59 but once 
activated by antigen-bearing dendritic cells, they 
can be drawn into the lung by means of their 
tissue-specific chemokine recep tors.58,59 In the 
lungs of smokers with COPD, CD8+ and CD4+ 
T cells express the tissue-specific chemokine 
receptors CXCR3, CCR5, and CXCR6,60-62 but 
they do not express CCR3 or CCR4, both of 
which are chemokine receptors expressed by 
CD4+ Th2 T cells in asthma.61,62 The ligands for 
CXCR3–CXCL10 (or interferon-inducible protein-10 
[IP-10]) and CXCL9 (or monokine induced by in-
terferon-γ [MIG]) are strongly expressed by struc-
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Figure 2. Lung Specimen from a Patient with Emphysema 
and COPD.
A 100-μm slice from the whole lung shows centrilobular 
emphysema, which is more prominent in the upper lobes 
(no staining). The square inset shows centrilobular 
 destruction and enlargement (hematoxylin and eosin). 
The oval inset shows a severe inflammatory infiltrate, 
consisting of alveolar macrophages, CD8+ T lympho-
cytes (immunostaining with antihuman CD8; counter-
stained with hematoxylin), and oth r cells, involving 
the alveolar wall and surrounding air spaces.
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tural cells in the airways and pulmonary arteries 
in patients with COPD but not in those of smok-
ers and nonsmokers without COPD. The expres-
sion of these receptors and their ligands corre-
lates with the severity of the disease.60-62
We refer to this chain of events as step 2 and 
propose that disease progression and severity at 
this point are determined by the ability of den-
dritic cells to stimulate T cells. This ability is 
modulated by immunoregulatory mechanisms: 
mild failure of these regulatory mechanisms re-
sults in GOLD stage 1 or stage 2; severe failure 
allows progression to what we call step 3 and 
GOLD stage 3 or stage 4 (Fig. 4).
Step 3 — Adaptive Immune Reaction
The CD8+ cytotoxic T cell is the predominant cell 
in large airways,63 small airways,64 and the lung 
parenchyma19,65-67 in COPD. The number of CD8+ 
T cells in the lung correlates with the degree of 
airflow obstruction and emphysema, suggesting 
that these cells cause tissue injury in COPD.68 
Any cell that displays MHC class I molecules can 
be a target for CD8+ cytolytic T cells. After a cyto-
lytic attack, target cells die of apoptosis or necro-
sis from the damage done by perforin, granulysin, 
or granzyme A or B, all of which are proteolytic 
enzymes released by CD8+ T cells69 in the lungs 
of patients with COPD.70,71
In the lungs of smokers with COPD and em-
physema, epithelial and endothelial cells under-
go apoptosis,72,73 and the number of these apop-
totic cells increases with the extent of smoking 
and correlates with the number of CD8+ T cells 
in the lung.19 Furthermore, cell survival seems to 
depend on signals from the integrin family of 
adhesion receptors, which continuously sense the 
extracellular milieu. Another signal for apopto-
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Figure 3. Initial Response to Cigarette Smoke — Step 1 in the Process Leading to COPD.
Cigarette smoke injures epithelial cells, which release “danger signals” that act as ligands for toll-like receptors (TLRs) in the epithelium. 
These actions trigger the production of chemokines and cytokines, which results in an innate inflammation. Products from the inflam-
matory cells may injure the extracellular matrix, leading to the release of TLR ligands and consequent TLR activation, which will promote 
further inflammation, tissue injury, and the production of antigenic substances. This chain of events may cause dendritic cells to mature 
and migrate to local lymph organs, where, if the conditions are favorable, T-cell activation may result, with progression of the disease. If 
the innate inflammation in step 1 is minimized or controlled, the inflammation will not progress to adaptive immunity, and the disease 
may be arrested. These processes are typical of smokers who have neither COPD nor Gold stage 1. GM-CSF denotes granulocyte–macro-
phage colony-stimulating factor, HSP heat-shock protein, ICAM-1 intercellular adhesion molecule 1, MCP-1 monocyte chemoattractant 
protein 1, and TNF tumor necrosis factor.
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sis in COPD could be the loss of cell contact with 
the extracellular matrix induced by breakdown 
of the matrix by proteases.74-76
The apoptosis and necrosis of epithelial and 
endothelial cells induced by CD8+ T cells and 
possibly proteases, which cell proliferation does 
not compensate for,65 most likely contribute to 
lung destruction in COPD.13 Furthermore, phago-
cytosis of apoptotic cells by alveolar macrophages 
is deficient in COPD,77 an abnormality that can 
increase the amount of antigenic material and 
that has been implicated in some autoimmune 
disorders.14,39,47,78
CD4+ T cells are also found in large numbers 
in the airways and parenchyma of smokers with 
COPD.7,67 These cells are activated and are oligo-
clonal; clones of CD4+ T cells appear in the lungs 
but not in the blood, suggesting that the accu-
mulation is the result of stimulation by antigens 
distributed throughout the lung.79 CD4+ T cells 
in the lungs of smokers with COPD express 
STAT4 and interferon-γ, further suggesting anti-
genic stimulation.54 The number of CD4+ T cells 
expressing interferon-γ correlates with the de-
gree of airflow obstruction,54 supporting the sug-
gestion that these cells, along with CD8+ T cells, 
play a role in the pathogenesis of COPD. The ef-
fector functions of the CD4+ T cell are mainly 
mediated by Th1 cytokines, which promote trans-
endothelial migration of inflammatory cells to 
the site of injury.23 The recruitment and activa-
tion of inflammatory cells, macrophages, neutro-
phils, eosinophils, CD4+ and CD8+ T cells, and 
B cells progress as COPD worsens.7,67,80 In COPD, 
the interaction between the chemokines CXCL10 
(or IP-10) and CXCL9 (or MIG), secreted by T cells, 
and their receptor, CXCR3, found in alveolar mac-
rophages, up-regulates the production of matrix 
metalloproteinase-12 by these cells, thereby facili-
tating lung destruction.62
The presence of B cells in lymphoid follicles 
has been reported in the airways and parenchy-
ma of patients with COPD and of mice exposed 
to cigarette smoke.7,81 Sequence analysis of rear-
ranged immunoglobulin genes in individual B-cell 
clones in these lymphoid follicles has revealed 
the presence of immunoglobulin-variable-region 
mutations in clonally related B cells, suggesting 
an antigen-driven selection process. The absence 
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Figure 4. Proliferation of T Cells — Step 2 in the Process Leading to COPD.
When step 1 is successful, mature dendritic cells migrate to local lymphatic 
organs, whereupon stimulation by toll-like receptors (TLRs) leads to the ex-
pression of CD80–CD86 and cytokines, creating a propitious milieu for T-
cell antigen presentation and proliferation into effector CD4+ type 1 helper 
(Th1) T cells and cytolytic CD8+ T cells. Interleukin-6, secreted by the den-
dritic cells, favors the production of effector T cells by overcoming the signals 
from regulatory T (Treg) cells. Upon activation, effector T cells express tis-
sue-specific chemokine receptors. Immune regulation or tolerance mecha-
nisms will determine at this stage the degree of proliferation of T-cell effec-
tors, homing, and eventually, disease severity. An absence of tolerance is 
associated with Gold stage 3 or stage 4, moderate tolerance with Gold 
stage 2, and full tolerance with Gold stage 1. MHC denotes major histo-
compati bility complex.
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of bacterial and viral products in the follicles sug-
gests that these oligoclonal B cells arise in re-
sponse to lung antigens.81 Nevertheless, viral and 
bacterial infections could be important in perpetu-
ating the inflammatory process and are regarded 
as the main cause of the exacerbations in COPD.15,67 
Such infections might trigger an immune re-
sponse that culminates in pulmonary damage.42
We refer to this chain of events as step 3 in 
the progression of COPD. We propose that en-
hanced dendritic-cell function, genetic predispo-
sition, and failure of immune regulation result 
in adaptive immunity and severe disease (GOLD 
stage 3 or stage 4) (Fig. 5).
Pulmonary inflammation in severe COPD in-
cludes large numbers of activated oligoclonal 
Th1 T cells,62,79 B cells,81 and CD8+ T cells, which 
persist for years after cessation of smoking,82 
suggesting a self-perpetuating process that is a 
feature of autoimmune diseases. This chain of 
events suggests that the adaptive immune re-
sponse in COPD, along with its persistence after 
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Figure 5. The Adaptive Immune Reaction — Step 3 in the Process Leading to COPD.
With the failure of tolerance or immune regulation in step 2, an adaptive immune inflammation (autoimmune) de-
velops in the lung, consisting of CD4+ type 1 helper (Th1) T cells, cytolytic CD8+ T cells, and IgG-producing B cells. 
Regulatory T cells (Treg) and γδ CD8+ T cells could modulate the severity of the adaptive immune inflammation. 
The resulting immune inflammation, induced by CD4+ Th1 T cells and consisting of activated innate immune cells 
producing oxidative stress and proteinases, along with cytolytic CD8+ T cells and B cells, leads to cellular necrosis 
and apoptosis, immune and complement deposition, tissue injury with airway remodeling, and emphysema, as well 
as the release of additional antigenic material, which perpetuates the process. In step 3, the full autoimmune pro-
cess has developed, producing the most severe disease (Gold stage 3 and stage 4). NO denotes nitric oxide, and 
ROS reactive oxygen species.
The New England Journal of Medicine 
Downloaded from nejm.org at CRAI UNIVERSITAT DE BARCELONA on March 27, 2013. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
mechanisms of disease
n engl j med 360;23 nejm.org june 4, 2009 2451
smoking cessation, might be due to a response 
to self-antigens.
E v idence of Au t oimmuni t y  
in COPD
Three types of evidence can be marshaled to es-
tablish that a human disease is autoimmune in 
origin: circumstantial, indirect, and direct.83 In 
the case of COPD, all three types of evidence have 
been established. The increased numbers of 
T cells and B cells in the lungs of patients with 
COPD constitute circumstantial evidence. In-
direct evidence of autoimmunity is provided by the 
presence of circulating antibodies against elastin 
in COPD and emphysema, along with the obser-
vation that CD4+ T cells cultured from the lungs 
of patients with COPD respond to elastin by se-
creting interferon-γ and interleukin-10. The extent 
of the response is proportional to the degree of 
emphysema, and the response can be blocked by 
MHC class II antibodies, which indicates that an-
tigen presentation is involved.84 Indirect evidence 
is also provided by the presence of circulating 
IgG autoantibodies against pulmonary epithelium 
and endothelium that have the ability to promote 
antibody-dependent, cell-mediated cytotoxicity and 
that participate in the antigen–antibody complex-
es that are deposited along with complement in 
the lung.85
Although antibodies reflect the microenviro-
mental availability of antigens, they are not neces-
sarily causal. Causality and direct evidence of 
immunity can be implied from the results of ex-
periments in rats injected with human umbilical-
vein endothelial cells. Antibodies against the en-
dothelial cells were produced in the rats, and 
emphysema developed in association with apop-
tosis of alveolar cells and an accumulation of 
CD4+ T cells in the lung.86 This study also 
showed that the antibodies against human endo-
thelial cells in the rats induced endothelial-cell 
apoptosis in vitro and caused emphysema when 
transferred to mice. Finally, the transfer of T cells 
isolated from the spleens of rats that were im-
munized with human endothelial cells also caused 
emphysema in immunocompetent rats.86
The presence of autoantigens and antibodies 
in COPD is not by itself direct evidence of cau-
sality. However, the properties of the autoanti-
gens, T cells, and antibodies in COPD, along with 
the findings in the animal model, support the 
idea that autoimmunity is important in the patho-
genesis of COPD.
W h y Some Smok er s e va de COPD
Immune regulation, genetic susceptibility, and the 
environment are factors that provide protection 
against or induce a predisposition to autoimmune 
diseases, and they may be important in COPD.42,43 
With time, the lungs of all smokers are damaged 
and release material with the potential for elicit-
ing an immune response. Not all smokers have a 
reaction to these antigens, however, and among 
those who do have a reaction, its intensity varies. 
These differences probably account for the wide 
range of disease severity in response to similar 
amounts of exposure to cigarette smoke.17,64,87
An important mechanism that controls T cells 
is mediated by CD4+CD25+FOXP3 regulatory 
T cells.88 A deficiency of regulatory T cells can 
impair the immune system’s tolerance for auto-
antigens and thereby lead to immune disease.89 
As compared with the lungs of people who have 
never smoked, the lungs of people who smoke but 
have normal lung function have a greater num-
ber of regulatory T cells. However, the lungs of 
smokers with COPD and emphysema90 have fewer 
regulatory T cells and less FOXP3 messenger RNA 
than the lungs of healthy smokers.84 This sug-
gests that regulatory T cells may regulate T cells 
in smokers with normal lung function, preventing 
development of the immune reaction.91 Another 
population of T cells with immunoregulatory 
properties, the γδ CD8+ T lymphocytes,92 is also 
increased in smokers with normal lung function 
but not in smokers with COPD.93 These findings 
point toward impaired immune regulation in 
smokers with COPD.
A characteristic of autoimmune diseases is 
their propensity to appear in families, and sev-
eral studies have shown an increased prevalence 
of airflow obstruction among smokers who are 
first-degree relatives of patients with COPD.94-96 
In addition, the maximal expiratory flows in twins 
who smoke are matched as closely as those in 
pairs of twins who never smoked,97 a finding that 
strongly suggests an underlying genetic suscep-
tibility. However, environmental factors (e.g., sec-
ondhand smoke) cannot be ruled out. Genetic 
studies in smokers have shown associations 
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among genes involved in oxidative processes and 
several mediators of inflammation, but no genes 
related to autoimmunity have been directly inves-
tigated.98
Cigarette smoke may also promote the devel-
opment of COPD through its influence on epige-
netic factors, such as chromatin acetylation. A 
reduction in histone deacetylase activity in the 
lung parenchyma, bronchial-biopsy specimens, 
and lung macrophages, mediated by oxidative 
stress, has been described in smokers with COPD, 
and this decrease is correlated with the severity 
of the disease and the intensity of the inflamma-
tory response.99
Finally, tobacco smoking can play an impor-
tant role in autoimmune diseases, probably by 
inducing apoptosis and influencing lymphocyte 
functions, both of which synergize with genetic 
factors to create an important increased risk for 
the development of rheumatoid arthritis and 
systemic lupus erythematous.100
Conclusions
There is mounting evidence that autoimmunity 
has a role in the pathogenesis of COPD. Although 
circumstantial, indirect, and direct evidence of the 
role of autoimmunity in COPD has been identi-
fied, no cause-and-effect relationship between 
autoimmunity and the mechanisms of COPD has 
been established. We hope that the evidence pre-
sented will stimulate the research needed to clar-
ify the role of autoimmunity in the pathogenesis 
of COPD.
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